[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP9901865A2 - Eljárás és gyógyszerkészítmény lipidkoncentráció szabályozására - Google Patents

Eljárás és gyógyszerkészítmény lipidkoncentráció szabályozására

Info

Publication number
HUP9901865A2
HUP9901865A2 HU9901865A HUP9901865A HUP9901865A2 HU P9901865 A2 HUP9901865 A2 HU P9901865A2 HU 9901865 A HU9901865 A HU 9901865A HU P9901865 A HUP9901865 A HU P9901865A HU P9901865 A2 HUP9901865 A2 HU P9901865A2
Authority
HU
Hungary
Prior art keywords
combination
pharmaceutical composition
greater extent
lipid concentration
regulating lipid
Prior art date
Application number
HU9901865A
Other languages
English (en)
Inventor
Thomas M. A. Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901865(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP9901865A2 publication Critical patent/HUP9901865A2/hu
Publication of HUP9901865A3 publication Critical patent/HUP9901865A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány egy ACAT inhibitőrból, példáűl (2,6-diizőprőpil-fenil)-{[(2,4,6-triizőprőpil-fenil)-acetil]-szűlfamát}-ból és egy HMG-CőAredűktáz inhibitőrból, példáűl atőrvasztatinból álló, hatékőnylipidregűlátőr kőmbinációra vőnatkőzik. A hatóanyagők kőmbinációjanagyőbb mértékben csökkenti a plazma VDL és LDL kőleszterint, ésnagyőbb mértékben növeli a HDL kőleszterint, mint az önmagában a kéthatóanyag bármelyike, amelynek eredményeként kevésbé atherőgenlipőprőtein prőfil alakűl ki. A kőmbináció eredményesen alkalmazhatóischaemicűs szindrómák kialakűlása által veszélyeztetett betegekben azendőgén vascűlaris endőtheliűm-függő aktivitásők helyreálításaérdekében végzett kezelésekre. ŕ
HU9901865A 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration HUP9901865A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02

Publications (2)

Publication Number Publication Date
HUP9901865A2 true HUP9901865A2 (hu) 1999-10-28
HUP9901865A3 HUP9901865A3 (en) 2000-06-28

Family

ID=21719566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901865A HUP9901865A3 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Country Status (27)

Country Link
US (3) US6124309A (hu)
EP (1) EP0858336B1 (hu)
JP (1) JPH11515025A (hu)
KR (2) KR100449604B1 (hu)
CN (2) CN1679953A (hu)
AR (1) AR004527A1 (hu)
AT (1) ATE348607T1 (hu)
AU (1) AU720853B2 (hu)
BG (1) BG64018B1 (hu)
BR (1) BR9611410A (hu)
CZ (1) CZ127198A3 (hu)
DE (1) DE69636783T2 (hu)
EA (1) EA000514B1 (hu)
ES (1) ES2279526T3 (hu)
GE (1) GEP20001898B (hu)
HK (1) HK1016509A1 (hu)
HU (1) HUP9901865A3 (hu)
IL (1) IL123902A (hu)
IS (1) IS4720A (hu)
NO (1) NO981961L (hu)
NZ (2) NZ319906A (hu)
PL (1) PL186714B1 (hu)
RO (1) RO120816B1 (hu)
SK (1) SK284142B6 (hu)
UA (1) UA46069C2 (hu)
WO (1) WO1997016184A1 (hu)
ZA (1) ZA969187B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
GEP20001898B (en) * 1995-11-02 2000-01-05 Warner Lambert Co Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
EP1514543A1 (en) * 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EE200100199A (et) * 1998-09-30 2002-06-17 Warner-Lambert Company Kateetrilpõhineva revaskularisatsiooni ennetamisevõi edasilükkamise meetod
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) 1999-10-15 2001-04-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Composes anti-ischemiques
KR20020050257A (ko) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
PL362244A1 (en) * 2000-09-01 2004-10-18 Sankyo Company, Limited Medicinal compositions
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
EP1326822A2 (en) 2000-10-11 2003-07-16 Esperion Therapeutics Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
CA2425674A1 (en) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
WO2003077896A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
WO2003087040A2 (en) * 2002-04-10 2003-10-23 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) * 2002-04-12 2008-11-26 興和株式会社 新規なトロンボモジュリン発現促進剤
PT2404890T (pt) 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
JPWO2005020996A1 (ja) 2003-08-29 2007-11-01 興和株式会社 リピド・リッチ・プラークの安定化方法及び破裂予防方法
WO2005046706A1 (ja) * 2003-11-17 2005-05-26 Toyo Shinyaku Co., Ltd. 松樹皮抽出物を含む脂質代謝改善剤
BR0318685A (pt) 2003-12-24 2006-12-19 Esperion Therapeutics Inc compostos de cetona e composições para controle de colesterol e usos relacionados
US20050234068A1 (en) * 2004-04-19 2005-10-20 Baldwin Dalton D Composition and method of decreasing renal ischemic damage
TW200605890A (en) * 2004-07-28 2006-02-16 Sankyo Co Pharmaceutical compositions for inhibiting arteriosclerosis
RU2007115900A (ru) * 2004-10-27 2008-11-10 Дайити Санкио Компани, Лимитед (Jp) Производные бензола, имеющие 2 или более заместителей
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US9597289B2 (en) 2006-04-26 2017-03-21 Rosemont Pharmaceuticals Ltd. Liquid oral simvastatin compositions
US20130254787A1 (en) 2006-05-02 2013-09-26 Invidi Technologies Corporation Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
CN102424663B (zh) * 2010-12-03 2013-08-14 天津滨江药物研发有限公司 一种阿托伐他汀氨基酸盐及其制备方法
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
CN103304496A (zh) * 2012-03-08 2013-09-18 南京工业大学 一种合成申嗪霉素方法
WO2013171100A1 (en) 2012-05-16 2013-11-21 Joachim Hans Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
NZ736344A (en) 2015-03-13 2024-08-30 Esperion Therapeutics Inc Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2020257573A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
HUT67341A (en) 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
WO1994009774A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Biologically active compounds and process therefor
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
GEP20001898B (en) * 1995-11-02 2000-01-05 Warner Lambert Co Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam

Also Published As

Publication number Publication date
NZ512484A (en) 2003-02-28
ES2279526T3 (es) 2007-08-16
SK55798A3 (en) 1999-06-11
DE69636783D1 (de) 2007-02-01
JPH11515025A (ja) 1999-12-21
EP0858336B1 (en) 2006-12-20
PL186714B1 (pl) 2004-02-27
HK1016509A1 (en) 1999-11-05
CZ127198A3 (cs) 1998-12-16
CN1201389A (zh) 1998-12-09
KR100449604B1 (ko) 2004-11-16
ZA969187B (en) 1997-05-29
SK284142B6 (sk) 2004-10-05
NO981961L (no) 1998-05-04
AU7253996A (en) 1997-05-22
BG102417A (en) 1999-01-29
IL123902A (en) 2003-01-12
BG64018B1 (bg) 2003-10-31
ATE348607T1 (de) 2007-01-15
KR20040029459A (ko) 2004-04-06
EA199800420A1 (ru) 1998-10-29
HUP9901865A3 (en) 2000-06-28
CN1217656C (zh) 2005-09-07
IL123902A0 (en) 1998-10-30
NZ319906A (en) 2000-02-28
UA46069C2 (uk) 2002-05-15
AR004527A1 (es) 1998-12-16
US6124309A (en) 2000-09-26
DE69636783T2 (de) 2007-10-18
IS4720A (is) 1998-04-17
PL326365A1 (en) 1998-09-14
US6143755A (en) 2000-11-07
BR9611410A (pt) 1999-01-05
KR19990067270A (ko) 1999-08-16
US6093719A (en) 2000-07-25
GEP20001898B (en) 2000-01-05
EP0858336A1 (en) 1998-08-19
WO1997016184A1 (en) 1997-05-09
RO120816B1 (ro) 2006-08-30
CN1679953A (zh) 2005-10-12
NO981961D0 (no) 1998-04-30
EA000514B1 (ru) 1999-10-28
AU720853B2 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
HUP9901865A2 (hu) Eljárás és gyógyszerkészítmény lipidkoncentráció szabályozására
FI951218A0 (fi) Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
DE69819748D1 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
NO952529D0 (no) Kombinasjon av en kolesterolbiosynteseinhibitor og en ktam-kolesterolabsorpsjonsinhibitor
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
DE59509751D1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
DE69710065D1 (de) Androsten-derivate
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
DE69629989D1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
SE9603725D0 (sv) New teatment
ATE314068T1 (de) Behandlung von seborrhoischer dermatitis
ITMI931649A1 (it) Derivati dell&#39;acido 2-ammino-4-fenil-4-osso butirrico
NZ527583A (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
DE69636907D1 (de) Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
UA35566C2 (uk) Лікарський засіб для профілактики і лікування порушень ліпоїдного і холестеринового обміну речовин і спосіб профілактики і лікування цих порушень
DE59505146D1 (de) Liposomen enthaltend darin verkapselte proteine, verfahren zu ihrer herstellung sowie diese liposomen enthaltende pharmazeutische und kosmetische zubereitungen
EP0820770A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und ein Antioxidans enthält
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
CA2233558A1 (en) Method and pharmaceutical composition for regulating lipid concentration
RU93004794A (ru) Стероидные производные, применение стероидных производных для снижения содержания холестерина, фармацевтические композиции на их основе, способ получения стероидных производных
BE900654A (fr) Composition pharmaceutique et procede de traitement de l&#39;excitation.